AstrazenecaAZN.NValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 16, 2026, Astrazeneca (AZN.N) trades at a P/E of 24.60x, P/B of 5.10x, P/S of 4.18x, and a dividend yield of 1.96%.
Longitudinal percentile comparison: P/E sits at the 24th percentile over the trailing 10Y window (vs. 24th percentile over 3Y); P/B sits at the 30th percentile over the trailing 10Y window (vs. 30th percentile over 3Y); P/S sits at the 22nd percentile over the trailing 10Y window (vs. 22nd percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 51st percentile within its industry and the 62nd percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 2.16%, ranking at the 81st percentile over the trailing 20Y window.
Cross-checking P/E against P/B, the two percentiles sit within 5.4 points of each other — a consistent signal from both angles. The P/E percentile sits lower within its industry than across the market as a whole — relatively cheaper next to direct peers. Of the 2.16% total shareholder yield, 1.96% is paid out as dividends and roughly 0.20% is implied to come from buybacks — both channels are meaningfully in play. Astrazeneca operates in the Manufacturing sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: NYSE: AZN · AZN
Want the full picture on whether Astrazeneca (AZN.N) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 24.60 | ||||||
| P/B (MRQ) | 5.10 | ||||||
| P/S (TTM) | 4.18 | ||||||
| Dividend Yield | 1.96% | ||||||
| Buyback + Div Yield | 2.16% |